WASHINGTON – National Association of Chain Drug Stores (NACDS) president and CEO Steven C. Anderson emphasized the role of community pharmacies in supporting patients taking GLP-1 medications during the Milken Institute’s 2026 Future of Health Summit on Friday, November 13.
Anderson joined health care leaders for a panel discussion on how pharmacists, health care providers, and insurers can collaborate to improve access to GLP-1 therapies and support patients throughout treatment.
During the discussion, Anderson highlighted findings from Beyond the Prescription: Community Pharmacy’s Role in Comprehensive GLP-1 Care, a Milken Institute report supported by NACDS and released November 11.
As CDR previously reported, the research found that community pharmacies already provide essential support for GLP-1 patients, including managing side effects, improving medication adherence, and addressing affordability challenges.

Anderson emphasized opportunities to expand these services through sustainable reimbursement models that compensate pharmacists for counseling, medication management, and other patient support services.
Complementary opinion research commissioned by NACDS found that 93% of current, former, and prospective GLP-1 users expressed confidence in pharmacists as a source for medication-related questions.
Anderson participated in the panel with Shantanu Agrawal, chief health officer at Elevance Health, and Charles “Chuck” Henderson, CEO of the American Diabetes Association. The discussion was moderated by Bertha Coombs, former senior health care reporter at CNBC.
The panel recording is available on the Milken Institute website.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
